Live Breaking News & Updates on Telmar Network Technology
Stay updated with breaking news from Telmar network technology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Odgers Berndtson Expands Technology Practice - Hunt Scanlon Media huntscanlon.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from huntscanlon.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Odgers Berndtson, the world s sixth largest global executive search firm, is pleased to announce Craig Brechner has joined the firm as a. ....
/PRNewswire/ Odgers Berndtson, the world s sixth largest global executive search firm, is pleased to announce Craig Brechner has joined the firm as a. ....
Highlander Post Views: 1,658 UCRâs School of Medicine is partnering with Emalex Biosciences in producing a biological treatment for stuttering and will lead the second phase of clinical trials. UCR will serve as the lead site for a Phase 2 clinical trial that will evaluate the effectiveness of ecopipam, an investigational drug being tested for the treatment of stuttering in adults and Tourette syndrome in pediatric patients. Emalex Biosciences who developed ecopipam, will conduct the clinical trial. Ecopipam currently treats talk and speech therapy. However, if the trials continue to show success and are later submitted to the U.S. Food and Drug Administration (FDA), ecopipam could become the leading biological medication to treat stuttering with FDA approval. Furthermore, ecopipam has the possibility of also treating children with Tourette syndrome, a type of disorder which involves âinvoluntary, repetitive movements and vocalization.â ....